Upgrade to SI Premium - Free Trial

Alto Neuroscience (ANRO)

18.26 -1.77 (8.84%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Form 4 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig May 29, 2026 4:17 PM - SEC Filing Form 3 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig May 29, 2026 4:16 PM - SEC Filing Form 8-K Alto Neuroscience, Inc. For: May 27 May 28, 2026 8:18 AM - SEC Filing Alto Neuroscience adds Karuna founder Miller to board May 28, 2026 8:03 AM - StreetInsider Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors May 28, 2026 8:03 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO) May 27, 2026 6:49 AM - StreetInsider Wolfe Research Starts Alto Neuroscience (ANRO) at Outperform May 22, 2026 5:57 AM - StreetInsider Alto Neuroscience (ANRO) PT Lowered to $36 at Baird May 18, 2026 7:32 AM - StreetInsider Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP May 15, 2026 5:09 PM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 14 Filed by: Etkin Amit May 15, 2026 5:06 PM - SEC Filing Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Point72 Asset Management, L.P. May 15, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Commodore Capital LP May 15, 2026 4:13 PM - SEC Filing Alto Neuroscience (ANRO) PT Lowered to $36 at Baird May 15, 2026 4:08 PM - StreetInsider Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award May 15, 2026 8:27 AM - BizWire Form SCHEDULE 13G Alto Neuroscience, Inc. Filed by: Sirenia Capital Management LP May 15, 2026 8:08 AM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Sanchez Ramiro May 14, 2026 5:00 PM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Cox Christopher Nixon May 14, 2026 4:59 PM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Manji Husseini May 14, 2026 4:58 PM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: Dreyfus Andrew May 14, 2026 4:57 PM - SEC Filing Form 4 Alto Neuroscience, Inc. For: May 12 Filed by: York Gwill May 14, 2026 4:56 PM - SEC Filing Form 8-K Alto Neuroscience, Inc. For: May 12 May 13, 2026 4:21 PM - SEC Filing Form 10-Q Alto Neuroscience, Inc. For: Mar 31 May 13, 2026 7:31 AM - SEC Filing Form 8-K Alto Neuroscience, Inc. For: May 13 May 13, 2026 7:04 AM - SEC Filing Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights May 13, 2026 7:03 AM - BizWire Alto Neuroscience Announces Participation in Upcoming Investor Conferences May 11, 2026 4:05 PM - BizWire BofA Securities Starts Alto Neuroscience (ANRO) at Buy May 4, 2026 4:16 PM - StreetInsider Alto Neuroscience reports positive Phase 2a data for depression drug May 4, 2026 8:03 AM - StreetInsider Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting May 4, 2026 8:03 AM - BizWire Alto Neuroscience begins Phase 2b trial for treatment-resistant depression April 21, 2026 8:03 AM - StreetInsider Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression April 21, 2026 8:03 AM - BizWire Form EFFECT Alto Neuroscience, Inc. April 21, 2026 6:05 AM - SEC Filing Alto Neuroscience (ANRO) files for 6M share offering by selling stockholders April 10, 2026 4:06 PM - StreetInsider Form S-3 Alto Neuroscience, Inc. April 10, 2026 4:01 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO) April 6, 2026 6:53 AM - StreetInsider Alto Neuroscience (ANRO) PT Lowered to $44 at Jones Trading April 2, 2026 8:04 AM - StreetInsider Form 8-K Alto Neuroscience, Inc. For: Apr 01 April 1, 2026 4:55 PM - SEC Filing ALTO NEUROSCIENCE reports phase 2 trial of ALTO-101 misses primary endpoint April 1, 2026 4:30 PM - StreetInsider Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements April 1, 2026 4:30 PM - BizWire Form ARS Alto Neuroscience, Inc. For: Dec 31 March 26, 2026 4:11 PM - SEC Filing Form DEFA14A Alto Neuroscience, Inc. March 26, 2026 4:09 PM - SEC Filing Form DEF 14A Alto Neuroscience, Inc. For: May 12 March 26, 2026 4:07 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO) March 18, 2026 7:57 AM - StreetInsider Alto Neuroscience (ANRO) PT Raised to $41 at Baird March 18, 2026 7:43 AM - StreetInsider Stifel Reiterates Buy Rating on Alto Neuroscience (ANRO) as co on track for ph2b TRD study for ALTO-207 March 17, 2026 5:58 PM - StreetInsider Alto Neuroscience (ANRO) PT Raised to $35 at Jefferies March 16, 2026 10:56 AM - StreetInsider Form 8-K Alto Neuroscience, Inc. For: Mar 16 March 16, 2026 7:08 AM - SEC Filing Alto Neuroscience raises $120 million in private placement financing March 16, 2026 7:03 AM - StreetInsider Alto Neuroscience Announces $120 Million Private Placement Financing March 16, 2026 7:03 AM - BizWire Form S-8 Alto Neuroscience, Inc. March 16, 2026 6:45 AM - SEC Filing Form 10-K Alto Neuroscience, Inc. For: Dec 31 March 16, 2026 6:11 AM - SEC Filing Form 8-K Alto Neuroscience, Inc. For: Mar 16 March 16, 2026 6:07 AM - SEC Filing Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights March 16, 2026 6:03 AM - BizWire Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum March 13, 2026 8:03 AM - BizWire Full Article List